ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 853–855. Portico. https://doi.org/10.1002/hon.3166_ot31
Authors:
Ian W. Flinn
Caron A. Jacobson
Loretta J. Nastoupil
Franck Morschhauser
Andrew Davies
Christian Buske
Paolo Corradini
Armando López‐Guillermo
Ran Reshef
Vinod Parameswaran
Alison R. Sehgal
Michael Tees
C Y Lui
Xue Wang
Sara Beygi
Nikolay Grechko
P. Bolsue
Alessandro Giovanetti
C. To
Michelle Nahas
Affiliated Authors:
Ran Reshef
Subjects:
Publication Type:
Article
Unique ID:
10.1002/hon.3166_ot31
Publication Date:
Data Source:
OpenAlex

Record Created: